Business
ViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies
ViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies\n\nViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies\n\n\nSeeks to Distribute its Future Products in Canada, USA and all other Approved International Cannabis Countries\n\n LOS ANGELES, CA--(Marketwired - May 15, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the company has completed Phase I testing under patents pending for delivering medical and recreational cannabinoids to the body. The testing was performed in British Columbia, Canada with THC and has proven very successful. The Company plans to conduct medical research and clinical trials to develop Cannabinoids-based pharmaceuticals and treatments for conditions including, but not limited to, psoriasis, fibromyalgia, PTSD, Depression, Anxiety and migraines. The Company will also be pursuing the \"Recreational Market\" in Canada with expansion plans into the USA once the proper legal standards are addressed. \"THC, CBD, and CDN are more commonly known Cannabinoids found in the Cannabis and Hemp plants but there are over 100 known Cannabinoids that our technology can be used for. As pharmaceutical companies develop different cannabinoids for treating various medical conditions our delivery system, we believe, will be the premiere way of dosing and delivering the medication transdermally,\" said CEO Dr. Chris Otiko. ViaDerma will be begin developing unique delivery systems for the effective delivery and dosage of recreational and medical cannabinoids and plans to start a grass roots product for both THC and non-THC Cannabinoids, both in a patch form, roll on and spray. The plans include distribution in every dispensary across Canada to start with, and add a website for global distribution.The Company's success of its first round of testing is compelling and the company plans to start continued Clinical Trials to ensure that the delivery system meets medical standards. The idea is to continue and expand testing to include pure Cannabinoid isolates...